Subtype
Malignant Endometrial Neoplasm
CI-CAN-00008980Explore in graph →
359 active trials4 approved drugs28 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00008980Explore in graph →
Clinical trials
1,198 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (112)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07146919 | AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer(ANGELICA) | withdrawn | Phase 1 / Phase 2 | 0 | Centre Leon BerardOTHER | 0 | Apr 23, 2026 | clinicaltrials |
| NCT02874430 | Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer | terminated | Phase 2 | 29 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 22, 2026 |
| clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05559879 | Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma | recruiting | Phase 1 / Phase 2 | 37 | University of Alabama at BirminghamOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT01164150 | Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06 | terminated | Phase 2 | 92 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT01244789 | Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer | active not recruiting | Phase 2 | 244 | Danish Gynecological Cancer GroupNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03694262 | The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)(EndoBARR) | completed | Phase 2 | 30 | Medical College of WisconsinOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07522697 | Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4(MITO END-4) | not yet recruiting | Phase 2 | 48 | National Cancer Institute, NaplesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06253494 | Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer | recruiting | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07516210 | Adaptive Radiotherapy for Safe Hypofractionation(ART-Hypo) | not yet recruiting | Phase 2 | 264 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT04486352 | A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer(EndoMAP) | recruiting | Phase 1 / Phase 2 | 148 | Alliance Foundation Trials, LLC.OTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07377734 | Intrauterine Injection of Type III Collage in FST of EC/AEH(2026ColECFerSp) | recruiting | Phase 2 | 30 | Wang JianliuOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05036681 | A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma | terminated | Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05870761 | Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma | active not recruiting | Phase 2 | 8 | Casey CosgroveOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06395519 | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies(ERADIC8) | recruiting | Phase 1 / Phase 2 | 120 | 858 Therapeutics, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07189871 | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors(BetaBart) | recruiting | Phase 1 / Phase 2 | 61 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07276360 | Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda(HypoRTCx-UG) | recruiting | Phase 2 | 278 | Uganda Cancer InstituteOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05112991 | Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer | recruiting | Phase 2 | 108 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT03617679 | Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer | completed | Phase 2 | 79 | University of Colorado, DenverOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT06036836 | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | completed | Phase 2 | 163 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Mar 19, 2026 | clinicaltrials |
| NCT04814108 | A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma | completed | Phase 2 | 92 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 4 | Mar 18, 2026 | clinicaltrials |
| NCT07319429 | Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification(FEMUS) | recruiting | Phase 2 / Phase 3 | 260 | Fudan UniversityOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05824481 | Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer | active not recruiting | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04393285 | Abemaciclib and Letrozole to Treat Endometrial Cancer | active not recruiting | Phase 2 | 53 | Gynecologic Oncology GroupNETWORK | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07453394 | QLS5132 Combination Therapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 626 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 6, 2026 | clinicaltrials |
| NCT06369155 | Azenosertib in Uterine Serous Carcinoma: Biomarker Study | recruiting | Phase 2 | 25 | Joyce Liu, MDOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT04781088 | Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 2 | 38 | Floor Backes, MDOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06710847 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors(SYLVER) | active not recruiting | Phase 1 / Phase 2 | 14 | GlaxoSmithKlineINDUSTRY | 7 | Feb 2, 2026 | clinicaltrials |
| NCT07371663 | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 266 | Beijing Tide Pharmaceutical Co., LtdINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07369986 | Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer(IMMUNE-SAVE) | not yet recruiting | Phase 2 | 30 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 0 | Jan 27, 2026 | clinicaltrials |
| NCT04576104 | Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer | active not recruiting | Phase 2 | 51 | Northwestern UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07054567 | A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer | recruiting | Phase 2 | 96 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05082025 | Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05481645 | Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus. | terminated | Phase 2 | 71 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06518564 | Avelumab and M1774 in ARID1A-mutated Endometrial Cancer | recruiting | Phase 2 | 25 | Panagiotis Konstantinopoulos, MD, PhDOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06463028 | Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer | recruiting | Phase 2 | 40 | Faeth TherapeuticsINDUSTRY | 1 | Dec 24, 2025 | clinicaltrials |
| NCT05454358 | Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP | terminated | Phase 2 / Phase 3 | 12 | Fudan UniversityOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT05106127 | Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem | not yet recruiting | Phase 2 | 28 | Evergreen Therapeutics, Inc.INDUSTRY | 0 | Dec 8, 2025 | clinicaltrials |
| NCT07070518 | Study of GV20-0251 in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 350 | GV20 TherapeuticsINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05383482 | Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 | completed | Phase 1 / Phase 2 | 22 | Laekna LimitedINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05997017 | Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer | recruiting | Phase 2 | 29 | Aadi Bioscience, Inc.INDUSTRY | 1 | Nov 13, 2025 | clinicaltrials |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | terminated | Phase 1 / Phase 2 | 8 | Alaunos TherapeuticsINDUSTRY | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05798611 | Study of ART0380 in Patients With Biologically Selected Solid Tumors(ARTIST) | terminated | Phase 2 | 36 | Artios Pharma LtdINDUSTRY | 3 | Nov 6, 2025 | clinicaltrials |
| NCT06677190 | Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin | recruiting | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT05902988 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 200 | Volastra Therapeutics, Inc.INDUSTRY | 1 | Nov 4, 2025 | clinicaltrials |
| NCT06481592 | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. | recruiting | Phase 2 | 60 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Oct 30, 2025 | clinicaltrials |
| NCT05169437 | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors(PAVO) | terminated | Phase 2 | 22 | Tempus AIINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT04106414 | Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment | active not recruiting | Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT05483023 | 18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy | withdrawn | Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 0 | Oct 14, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Apr 23, 2026source: clinicaltrials